SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending amid community excitement and anticipation of a breakout, with many members expressing bullish sentiment using terms like "WAGMI" (We're All Gonna Make It). Some traders are eyeing a potential short squeeze, while others focus on the broader potential of the Solana ecosystem, including meme coins. There are those, however, who are concerned about potential dumps.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as the community rallies around its core belief in decentralized systems and a shared vision of financial freedom on the Solana network, which is captured in its ticker name. Community members are actively sharing positive sentiment and emphasizing the project's resilience, long-term potential, and strong community, viewing it as more than just a meme coin. The discussion highlights the potential for significant growth and a strong belief in the future of Web3.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending amid renewed interest in meme stocks, sparked by a White House social media post referencing the company. The community is actively discussing potential short squeezes and reminiscing about the stock's 2021 surge, with some drawing comparisons to other trending stocks.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, with many hoping for a "triple beat" and positive guidance. The community is also closely watching for potential rate cuts and any news regarding S&P 500 inclusion. Optimism is high, with some predicting a significant price surge if key resistance levels are broken.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to renewed trading momentum and discussions around its low float, with some traders speculating about a potential short squeeze. The company's recent earnings report, highlighting strong revenue growth but a net loss, is also a key point of discussion. Community members are actively debating potential price movements and trading strategies, with some expressing caution about its volatility.

Pump.fun

$PUMP is trending as the community rallies around the "We're All Gonna Make It" ($WAGMI) narrative, emphasizing community support and long-term goals. Some users highlight the upcoming 6-month milestone and growing mindshare, while others discuss potential for significant gains within the Solana meme coin ecosystem.

Smart Logistics Global Ltd. operates as a business-to-business contract logistics provider, specializing in industrial raw materials line-haul transportation. The company develops a smart logistics digital ecosystem for road transport by leveraging innovation, digital analytics, and infrastructure development. It enhances supply chain efficiency, shortens transit times, and improves client visibility using its integrated platform. Its services cater to a diverse range of industries including manufacturing, construction, and FMCG (Fast-Moving Consumer Goods), enabling seamless and cost-effective movement of goods across regional and national networks. The company was founded by Kwok Chiu Hue on October 8, 2020 and is headquartered in Hong Kong.

Smart Logistics Global Ltd.

Smart Logistics Global Limited Ordinary Shares

SLGB is trending due to its volatile price action and recent IPO status, with traders actively discussing potential short squeezes and price targets. Community members are also comparing it to other low-float Chinese stocks that have experienced significant gains, while some express concerns about potential manipulation. The stock's low float and recent price swings are key discussion points.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp ($UAMY) is trending due to overnight price movement potentially linked to discussions surrounding a deal with Larvotto Resources (LRV). The community is debating whether a deal is still viable after an initial rejection, with some speculating about government intervention and the potential for dilution. Broader concerns about rare earth element trade with China are also fueling the conversation, though UAMY focuses on antimony, a critical mineral, and some see this as an overreaction to a China REE trade truce.

Klarna Group Plc operates as an investment holding company. It provides an e-commerce payment solutions for merchants and shoppers. The firm connect an array of different financial services and commerce organizations, from PSPs, traditional banks, card networks and open banking providers, to commerce enablers, technology partners, in-store payments providers and shipping and return logistics providers. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending as discussions focus on its AI capabilities and recent partnerships with major players like Google and Qatar Airways. The community is weighing its growth potential in the BNPL sector against concerns about the broader economic climate and the stock's performance since its IPO. Some investors view Klarna as undervalued, particularly compared to competitors, while others express caution regarding its business model and potential for market volatility.

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

BridgeBio is trending due to positive Phase 3 results for its drug BBP-418 in treating LGMD2I/R9, sparking community discussion around its potential acquisition and future FDA approval. Investors are optimistic about the clinical data and potential blockbuster status, while some debate whether to "sell the news" or hold for long-term gains. The community also discusses the company's diversified pipeline and potential for further upside, despite concerns about its current market capitalization.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza

Cidara Therapeutics wins FDA Breakthrough Therapy tag for CD388 for the prevention of seasonal influenza. Stock rises.

Cidara Therapeutics, Inc. (CDTX) on Thursday said that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its drug CD388 for the prevention of influenza A and B in adults and adolescents who are at higher risk of disease-related complications.The new designation is in addition to the Fast Track designation granted to the drug by the agency in June 2023. CEO Jeffrey Stein said that the designations underscore the importance of the drug as a potential new non-vaccine prophylactic for seasonal influenza.“Individuals who have chronic medical conditions, advanced age, or are immune compromised may not be adequately protected by current vaccines, leaving them at higher risk for infection and complications from flu. As a long-acting prophylactic drug, CD388’s activity does not rely on an immune response, making it a potential prevention option for high-risk individuals as well as those for whom vaccines are contraindicated,” he <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/09/3164062/0/en/Cidara-Therapeutics-Receives-U-S-FDA-Breakthrough-Therapy-Designation-for-CD388-in-Seasonal-Influenza-Prevention.html">added</a>.The Breakthrough Therapy designation was awarded to the drug based on the results of a study in which CD388 provided statistically significant prevention of seasonal influenza in healthy unvaccinated adults aged 18-64. The company is now looking toward advancing the drug through its ongoing late-stage trial.The Breakthrough Therapy designation is intended to expedite the review of medicines that treat a serious or life-threatening condition. Benefits of the designation include eligibility for priority review and the FDA’s organizational commitment to involving senior management to guide the company on the most efficient route to approval, the company noted.Shares of the company rose 8% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CDTX">CDTX stock</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1360/118;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_09_at_12_16_14_PM_png_11f3dc4644.webp" alt="CDTX's Sentiment Meter and Message Volume as of 12:16 p.m. ET on Oct. 09, 2025 | Source: Stocktwits" width="1360" height="118"><figcaption>CDTX's Sentiment Meter and Message Volume as of 12:16 p.m. ET on Oct. 09, 2025 | Source: Stocktwits</figcaption></figure>H.C. Wainwright analyst Sara Nik subsequently raised the firm’s price target on Cidara Therapeutics to $150 from $110 while keeping a ‘Buy’ rating on the shares. The new price target implies a potential upside of over 52% from the stock’s closing price on Wednesday.CDTX stock nearly quadrupled in value this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lyft-partners-with-tensor-to-deploy-hundreds-of-avs-on-its-platform/ch67uQtR3KC">Lyft Partners With Tensor To Deploy Hundreds Of AVs On Its Platform</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cidara Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral

The Breakthrough Therapy designation was awarded to the drug based on the results of a study in which CD388 provided statistically significant prevention of seasonal influenza in healthy unvaccinated adults aged 18-64.

Equity

The Breakthrough Therapy designation was awarded to the drug based on the results of a study in which CD388 provided statistically significant prevention of seasonal influenza in healthy unvaccinated adults aged 18-64.


CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program

Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing.

U.S. equities declined in Wednesday’s afternoon trade as investors cautiously await the release of key economic data this week, including the third estimate of gross domestic product (GDP) for the second quarter (Q2) on Thursday, and the personal consumption expenditures (PCE) price index on Friday.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was down 0.39% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq, fell 0.6%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, declined 0.31%.Here are the top stocks making the biggest moves in Wednesday’s midday trade:<a href="https://stocktwits.com/symbol/LAC">Lithium Americas Corp. (LAC)</a>Lithium Americas’ shares skyrocketed over 96% in Wednesday’s afternoon trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lithium-americas-stock-surge-captures-wall-street-attention-here-is-why/chD1GtUR33g">confirmed</a> that it is in talks with the U.S. Department of Energy and its joint venture partner General Motors Co. (GM) in the Thacker Pass lithium project over the renegotiation of a $2.26 billion Energy Department loan.<a href="https://stocktwits.com/symbol/LAC">LAC stock</a> is up 101% year-to-date.<a href="https://stocktwits.com/symbol/BABA">Alibaba Group Holdings (BABA)</a>Alibaba’s U.S.-listed shares surged more than 9% in Wednesday’s afternoon session after the company announced plans to boost investment in artificial intelligence by over $53 billion.<a href="https://stocktwits.com/symbol/BABA">BABA stock</a> is up 110% year-to-date.<a href="https://stocktwits.com/symbol/QURE">uniQure NV (QURE)</a>uniQure shares soared more than 260% on Wednesday afternoon after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uniqure-stock-rises-pre-market-after-investigational-huntingtons-disease-drug-slows-disease-in-trial/chD1GAOR33X">said</a> that a high dose of its experimental gene therapy AMT-130 demonstrated a statistically significant slowing of disease progression in Huntington’s disease in an early-to-mid stage trial.<a href="https://stocktwits.com/symbol/QURE">QURE stock</a> is up 178% year-to-date.<a href="https://stocktwits.com/symbol/IREN">IREN (IREN)</a>IREN shares surged over 16% on Wednesday afternoon following an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/iren-stock-surged-15-percent-today-here-is-a-price-target-update/chD1drjR33t">announcement</a> by the company that it has doubled its AI Cloud capacity to a total of 23,000 GPUs (graphic processing units), supporting the company’s goal of achieving more than $500 million in annualized AI Cloud revenue by the first quarter of 2026.<a href="https://stocktwits.com/symbol/IREN">IREN stock</a> is up 393% year-to-date.<a href="https://stocktwits.com/symbol/CDTX">Cidara Therapeutics Inc. (CDTX)</a>Cidara shares gained over 21% in Wednesday’s afternoon trade after the company announced plans for a Phase 3 study for CD388, a non-vaccine preventative of seasonal influenza.<a href="https://stocktwits.com/symbol/CDTX">CDTX stock</a> is up 232% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/scott-bessent-surprised-by-strength-of-fed-chair-candidates/chD1cDJR33N">Scott Bessent Says He’s Surprised By Strength Of Fed Chair Candidates: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Today

Lithium Americas’ shares skyrocketed over 96% in Wednesday’s afternoon trade after the firm confirmed that it is in talks with the Energy Department and GM over the $2.6 billion Thacker Pass project loan.

Cidara Therapeutics (CDTX) Upgraded to Buy: Here's What You Should Know

Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Has Black Diamond Therapeutics (BDTX) Outpaced Other Medical Stocks This Year?

Here is how Black Diamond (BDTX) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.

Shares of Cidada Therapeutics doubled in value on Monday&nbsp;and jumped in after-hours trading as the biotech firm released positive results from a trial of its flu drug candidate,&nbsp;managing to offset pressure from plans for a $250 million share offering.Cidara will offer all shares, and underwriters will receive a 30-day option to buy up to 15% more shares.&nbsp;J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor are leading the deal.&nbsp;The disclosure&nbsp;follows a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cidara-therapeutics-market-cap-doubles-after-investigational-drug-shows-positive-results-in-preventing-influenza/chm5alCRRdd">mid-stage trial of CD388</a>, a long-acting antiviral being developed to protect against seasonal flu.&nbsp;In the trial, which enrolled healthy adults between 18 and 64 who had not been given flu vaccines, CD388 was administered in three single doses.Each dose showed statistically meaningful protection against the flu over a 24-week period, with the highest dose offering up to 76% protection.Cidara said the treatment was well tolerated at all tested levels, with no significant safety concerns.Based on the outcome, the company has formally asked the U.S. Food and Drug Administration (USFDA) to hold a meeting to review the findings and discuss next steps for a Phase 3 trial.CD388 is being developed using Cidara’s Cloudbreak platform and is designed to offer once-per-season protection against both influenza A and B viruses.&nbsp;The company expects to share further results at upcoming medical meetings.Following the update, H.C. Wainwright raised its price target on Cidara Therapeutics to $53 from $41, citing strong mid-stage trial results for CD388 and boosting its success probability to 75%.&nbsp;RBC Capital also lifted its target to $75 from $35, calling CD388 a potentially groundbreaking long-acting flu preventative.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 31,400% surge in 24-hour message volume.One user said Cidara’s rally was unusual for a company announcing a large capital raise, warning short sellers to be cautious.&nbsp;<stembedurl>https://stocktwits.com/Stmkr/message/618765398</stembedurl>Another user noted that no price had been set for the offering yet and said they planned to watch how the situation unfolds in the next session.<stembedurl>https://stocktwits.com/Lstreak/message/618734296</stembedurl>The stock has risen 64.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cidara Therapeutics Stock Jumps After-Hours As Strong Flu Trial Data Outweighs $250M Share Offering

The offering is being led by J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor.

Cidara Therapeutics, Inc. (CDTX) on Monday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cidara.com/news/cidara-therapeutics-announces-positive-topline-results-from-its-phase-2b-navigate-trial-evaluating-cd388-a-non-vaccine-preventative-of-seasonal-influenza/">announced</a> positive results from its mid-stage trial evaluating CD388 for the prevention of seasonal influenza in healthy unvaccinated adults aged 18 to 64.Cidara’s shares nearly doubled in value as of Monday afternoon.Single doses of 450mg, 300mg, and 150mg of CD388 conferred 76%, 61%, and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo, the company said. The doses were administered at the beginning of the flu season.CD388 was well-tolerated at all doses with no unexpected dose-limiting treatment-emergent adverse events observed, the company added.CD388 is not a vaccine. Instead, it is an investigational drug-Fc conjugate (DFC), or low molecular weight biologics, which are designed to function as long-acting small molecule inhibitors.As it is not a vaccine, its activity is not reliant on an immune response and, thereby, is expected to be efficacious in individuals regardless of immune status.CEO Jeffrey Stein stated that the trial results reinforce the company’s confidence in the potential of CD388 to provide seasonal protection against influenza A and B.Cidara stated that it has submitted a request to the U.S. Food and Drug Administration to review the results of the mid-stage trial and discuss the design and timing of a late-stage trial.Following the update, H.C. Wainwright raised its price target on Cidara to $53 from $41 and kept a ‘Buy’ rating on the shares.The new price target implies a 152% upside to the stock’s closing price on Friday.The analyst further increased the probability of success for CD388 to 75% from 60% based on the positive mid-stage trial data.RBC Capital also raised the firm's price target on Cidara Therapeutics to $75 from $35 while keeping an 'Outperform' rating on the shares. The results from the recent study position CD388 as a potential groundbreaking, long-acting flu preventative that could combine and enhance the benefits of existing vaccines and prophylactics, it said.On Stocktwits, retail sentiment around Cidara soared from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume increased from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_23_at_1_07_39_PM_png_569e678349.webp" alt="CDTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on June 23, 2025 | Source: Stocktwits" width="627" height="67"><figcaption>CDTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on June 23, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user highlighted the company’s debt-free status and strong cash position.<stembedurl>https://stocktwits.com/Vulcooo/message/618688709</stembedurl>Cidara ended the first quarter with $174.5 million in cash, cash equivalents, and restricted cash.<a href="https://stocktwits.com/symbol/CDTX">CDTX stock</a> is up by about 56% this year and by about 272% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/compass-pathways-stock-slumps-after-positive-late-stage-trial-results-from-psychedelic-drug-underwhelm-analysts/chm59LwRRdc">Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Cidara Therapeutics’ Market Cap Doubles After Investigational Drug Shows Positive Results In Preventing Influenza In Mid-stage Trial

Single doses of 450mg, 300mg, and 150mg of CD388 conferred 76%, 61%, and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo, the company said.

Cidara Therapeutics: A Strong Buy on Promising Trials and Strategic Milestones

Cidara Therapeutics (CDTX Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Stringer...

CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX CDTX INVESTOR NOTICE: ROSEN, TOP...

Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. Its platform, Cloudbreak, enables development of novel drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Cidara Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

CDTX
Cidara Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CDTX News

CDTXCidara Therapeutics Inc